BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Creabilis Therapeutics Appoints Dr David Roblin as Chief Medical Officer


8/4/2011 10:53:51 AM

LUXEMBOURG, August 4, 2011 /PRNewswire/ --

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announces today that Dr David Roblin has been appointed Chief Medical Officer.

Dr Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years and which has seen him deliver several drugs to the market. He has held leadership roles in Pfizer and Bayer across a wide range of therapy areas in research, development and commercial roles. At Pfizer, Dr Roblin was most recently Senior Vice President, Head of Research and Site Head for European R&D. Before joining Pfizer as Head of the Company's European Clinical Research and Development organisation, Dr Roblin held the position of Head of Anti-Infectives at Bayer Medical Affairs. Dr Roblin previously practiced medicine and is a Fellow of the Royal College of Physicians and Member of the Faculty of Pharmaceutical Physicians.

In addition to Dr Roblin's leadership roles in pharma, he has also chaired the Research Director's Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a $2bn public-private partnership with the European Commission. He is currently an advisor at NOCRI in the NHS, a non-executive director of Xceleron and an advisor to a number of venture funds.

Dr David Roblin, commenting on his appointment, said: "Creabilis has reached an exciting time in its development with its lead drug candidate, CT327, recently having demonstrated promising Phase IIa results in both psoriasis and atopic dermatitis, with ongoing studies in pain. I look forward to working with the Company as it progresses CT327 and its pipeline of potential new medicines for significant inflammatory and autoimmune conditions."

Dr Eliot Forster CEO of Creabilis said: "It is reflection of Creabilis' potential that we have been able to attract a Chief Medical Officer of David's calibre and reputation. He has vast experience not only in clinical development, but across the broader drug development pathway and pharmaceutical industry as a whole. This can only serve to benefit Creabilis as we progress our pipeline of valuable drug candidates."

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.

Creabilis' lead product is CT327 a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis and is undergoing proof-of-concept studies in pain. CT340 is a potent TrkA kinase inhibitor under development for the treatment of conditions in which TrkA kinase inhibition is implicated, including inflammatory arthritis and pain. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions, such as rheumatoid arthritis. Earlier-stage projects include a number of highly promising candidates for dermatological and wider indications.

Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners and Neomed.

For more information, please visit: http://www.creabilis-sa.com

For further information please contact:

Creabilis
Eliot Forster
eforster@creabilis-sa.com
Creabilis SA
5 rue Jean Monnet L-2810 LUXEMBOURG

Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44(0)20-7282-1050
E-mail: nina.enegren@citigatedr.co.uk

SOURCE Creabilis SA



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES